ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial

There is an urgent need for more effective therapies in glioblastoma (GBM). Data from the single arm UKT-03 trial (Glas et al., J Clin Oncol 27, 1257, 2009) suggested that combined lomustine/temozolomide (CCNU/TMZ) therapy might have superior activity in MGMT-methylated GBM. The phase III CeTeG/NOA-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Herrlinger, Ulrich, Tzaridis, Theophilos, Mack, Frederic, Steinbach, Joachim, Schlegel, Uwe, Sabel, Michael, Hau, Peter, Kortman, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Tabatabai, Ghazaleh, Ringel, Florian, Schmidt-Graf, Friederike, Brehmer, Stefanie, Weyerbrock, Astrid, Bullinger, Lars, Vajkoczy, Peter, Vatter, Hartmut, Schäfer, Niklas, Kebir, Sied, Weller, Johannes, Stummer, Walter, Simon, Matthias, Keil, Vera, Nelles, Michael, Fimmers, Rolf, Pietsch, Torsten, Hattingen, Elke, Coch, Christoph, Glas, Martin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5691928/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.049
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi